Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
These orders are from international government tenders in South Africa, Tanzania, and Kenya, as well as from international agencies WHO/UNFPA, NGOs like MSI and PSI
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Subscribe To Our Newsletter & Stay Updated
